



Vitamin D Analog “DA2HE” to Treat and Prevent Polyps, Hyperplastic Intestinal Disorders

[View U.S. Patent No. 8,785,422 in PDF format.](#)

WARF: P120347US02

Inventors: Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Agnieszka Glebocka

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a vitamin D analog showing strong cell selectivity that may provide therapy for some cancers as well as intestinal disorders like Crohn's and celiac disease.

Overview

The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D₃, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone mobilizes calcium from bones and increases intestinal absorption of dietary calcium. Effective therapeutic concentrations can lead to hypercalcemia; a condition characterized by elevated blood calcium levels, alterations in mental status, muscle weakness and calcification of soft tissues and organs such as the heart and kidneys. Therefore, a need exists for new compounds that provide desirable therapeutic effects without causing dose-limiting hypercalcemia.

The Invention

UW–Madison researchers have developed a vitamin D analog, seco-A-2,19-dinor-1,25-dihydroxyvitamin D₃. Known as DA2HE, the compound exhibits high activity *in vivo*, especially in intestinal tissues. Relatively low receptor binding, differentiation and transcription activities suggest strong cell selectivity for use against polyps, some cancers and intestinal disorders. The compound's high intestinal calcium transport activity may be useful against bone diseases.

Applications

- Therapy for polyps and colon cancer
- Treating and preventing Crohn's disease, ulcerative colitis, celiac disease and other intestinal disorders
- Treating bone diseases

Key Benefits

- High intestinal activity
- Potential for strong cell selectivity
- Less likely to cause dose-limiting hypercalcemia than calcitriol
- Can be administered in many forms

Additional Information

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

• [Margaret Clagett-Dame](#)

Tech Fields

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850

- [Therapeutics & Vaccines : Autoimmune disorders](#)
- [Therapeutics & Vaccines : Oncology](#)
- [Therapeutics & Vaccines : Vitamin D](#)

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850